Tenpoint Therapeutics, Visus Therapeutics announce merger

Key takeaways:

• The merged company plans to file a new drug application for its presbyopia-correcting eye drop in 2025.
• Henric Bjarke has been appointed as CEO.

Tenpoint Therapeutics and Visus Therapeutics announced the completion of their merger, according to a press release.

The merger will support the development of the presbyopia-correcting eye drop Brimochol PF (carbachol and brimonidine, Visus Therapeutics), which is on track for a new drug application filing with the FDA in the first half of 2025. The combined company’s pipeline also includes TPT-161, a novel small molecule designed to reverse cataract formation, and TPT-005, a cell therapy targeting retinal pigment epithelium cell replacement for geographic atrophy.

A crossover financing round initiated by the merger will include AdBio Partners, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital, Qiming Venture Partners USA and Sofinnova Partners, the release said.

Henric Bjarke has been appointed as CEO of the merged company.

“As we relaunch Tenpoint as a combined entity with Visus, we are excited to lead with a robust ophthalmology pipeline, starting with Brimochol PF, a near-term therapeutic medicine for presbyopia alongside other innovative therapies to treat cataract and geographic atrophy,” Bjarke said in the release. “With our combined teams, we have the right expertise to develop and successfully launch innovative products with the potential to be first and best in class in ophthalmic medicines.”

Published by:

Read more about

This post was originally published on this site